Related Experiment Video
Updated: Jun 21, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Development of somatostatin receptor subtype selective agonists through combinatorial chemistry
1Department of Endocrinology and Chemical Biology, Merck Research Laboratories, Rahway, NJ 7065, USA. susan_rohrer@merck.com
Abstract:
Non-peptide agonists of each of the five somatostatin receptors were identified from a combinatorial mixture library and three follow-up libraries. The initial library (20 x 20 x 79) was patterned after a lead structure which was identified by screening a set of molecules selected on the basis of molecular modeling of known peptide agonists of the somatostatin subtype-2 receptor (SSTR2). A second library with increased complexity (21 x 22 x 147) was designed around the same lead structure. Third and fourth libraries of aryl-indole compounds were designed, based on information that had been obtained by screening the first two libraries in five somatostatin receptor ligand-binding assays. Actives were chosen based on potency and receptor subtype selectivity profiles. The identity of each subtype selective compound present in active mixtures was determined by an iterative deconvolution process using resins archived from each step of the original synthesis. The approach of complex mixture screening was well validated with each of the five somatostatin receptors. The advantages of mixture screening with respect to manpower requirements, reagent consumption, and time to identify an active pure compound from a mixture were well illustrated in the course of this work. The availability of these high affinity, subtype selective agonists for each of the somatostatin receptors provided a direct approach to defining their physiological functions. In vitro experiments demonstrated the role of the somatostatin subtype-2 receptor (SSTR2) in inhibition of glucagon release from mouse pancreatic a-cells and the somatostatin subtype-5 receptor (SSTR5) as a mediator of insulin secretion from pancreatic b-cells. Both receptors regulated growth hormone release from the rat anterior pituitary gland.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Spare Receptors
Dose-Response Relationship: Selectivity and Specificity
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with one...
